Estimation of the Potential Benefits of Meningococcal Vaccination in Children at 9 and 12 Months of Age Using a Predictive Mathematical Model

Relevance. To address the issue of including vaccines against meningococcal infection (MI) in the Russian National Immunization Schedule (NIS), convincing arguments must be presented that demonstrate not only epidemiological, but also economic benefits.

Aim of this study was conducted to confirm them.

Materials & methods. For calculating epidemiological consequences, a dynamic predictive simulation model was constructed to compare the potential epidemiological burden of the disease in the current vaccination scenario (no MI vaccination in the NIS) and a new scenario involving vaccination of children aged 9 and 12 months with the MenACWY-d vaccine. The epidemiological outlook for meningococcal infection was assessed based on the dynamics of the main indicators of its prevalence in the General population that developed in previous years, taking into account the impact of double vaccination of children at 9 and 12 months on the survival period of each age cohort vaccinated in 2019–2034. The aim is to assess the predicted socio-economic consequences for different scenarios: while maintaining the current vaccination algorithm and including in the NIS vaccination against MI of all children aged 9 and 12 months using mathematical modeling.

Results and discussion. The greatest impact on reducing the number of clinical cases of the disease will be achieved in the age cohorts 0–1 years (-89%), 1–2 years (-84.5%), 3–6 years (-73.6%). Model calculations show that due to double vaccination of children under one year of age, 571 deaths can be expected to be prevented by 2034, which is equivalent to a reduction in losses of 40,509 years of life ahead and a social gain of 104.7 billion rubles in the monetary equivalent of the cost of these years (cumulative total). At the same time, taking into account the prevented cases of the disease, the total monetary equivalent of the benefits of society will begin to exceed the cost of vaccination earlier than in four years.

Conclusions thus, even an underestimated estimate of benefits that does not take into account the total amount of damage prevented (prevention of 571 deaths, loss of 40,509 years of life and 104.7 billion rubles in monetary terms of the cost of years of life to come), indicates the obvious importance of expanding the NIS and including vaccination of children aged 9 and 12 months from meningococcal infection.

1. Steinglass R. Routine immunization: an essential but wobbly platform. Global Health: Science and Practice, November. 2013;1(3):295–301.

2. Kovtun OP, Romanenko VV, Kazakevich NV, Savvina NV. Regional vaccine prevention program: ways of creation, achievements and prospects. Pediatric Pharmacology. - 2010. - T. 7. - No. 4. - P. 19–24 (In Russ.).

3. Sanitary and Epidemiological Rules of SP 3.1.3542-18 «Prevention of meningococcal infection» registered with the Ministry of Justice of Russia on January 9, 2019. No. 53254 (In Russ.).

4. Adapted from the State Report «On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2017» Rospotrebnadzor of the Russian Federation. Available at: https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=10145 (In Russ.).

5. Vyse, A., Anonychuk, A., Jakel, A., et al. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev. Anti Infect. Ther. 2013;11(6):597–604.

6. Rosenstein, N.E., Perkins, B.A., Stephens, D.S., et al. Meningococcal disease. N. Engl. J. Med. 2001;344(18):1378–1388.

7. Thompson, M.J., Ninis, N., Perera, R., et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006;367(9508):397–403.

8. Cohn, A.C., MacNeil, J.R., Harrison, L.H., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin. Infect. Dis. 2010;50(2):184–191.

9. Chang, Q., Tzeng, Y.L., Stephens, D.S. Meningococcal disease: changes in epidemiology and prevention. Clin. Epidemiol. 2012;4:237–245.

10. Lawrence, C. K., Boggess, K.A., & Cohen-Wolkowiez, M. Bacterial Meningitis in Infants. Clin. Perinatol. 2015;42(1):29–45.

11. Larrauri, A., Cano, R., Garcia, M., & Mateo, S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23:4097–4100

12. Lingani C, Bergeron-Caron C, Stuart JM, et al. Meningococcal meningitis surveillance in the African meningitis belt, 2004–2013. Clin Infect Dis 2015;61(Suppl 5):S410–S415.]

13. Diomande FV, Djingarey MH, Daugla DM, et al. Public health impact after the introduction of PsA-TT: The first 4 years. Clin Infect Dis 2015;61(Suppl 5):S467–S472]

14. WHO vaccine-preventable diseases: monitoring system. 2020 global summary. Available at: https://apps.who.int/immunization_monitoring/globalsummary/schedules (as of 08/20/2020)

15. Rospotrebnadzor RF. Federal statistical observation form No. 2 «Information on infectious and parasitic diseases», annual, 2019

16. Federal State Statistics Service. Available at: https://www.gks.ru/folder/12781 (date of treatment 08/20/2020) (In Russ.).

17. Cohn, A.C., MacNeil, J.R., Clark, T.A., et al. Centers for Disease, C., Prevention: Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2013 Mar 22;62(RR-2):1–28.

18. Sáfadi MA, Bettinger JA, Maturana GM et al. Evolving meningococcal immunization strategies. Expert Review of Vaccines. 2014;14(4):1–13.

19. Forecast of socio-economic development of the Russian Federation for the period up to 2036 by the Ministry of Economic Development of Russia (baseline scenario). Available at: http://old.economy.gov.ru/minec/about/structure/depmacro/201828113 (date of treatment 08/20/2020)

20. Prokhorov B.B., Shmakov D.I. Estimation of the cost of statistical life and economic damage from health losses. Problems of forecasting. 2002;3:125–135 (In Russ.).

21. Gómez J. A., Malbrán P. Wetzler, et al. Estimation of the real burden of invasive meningococcal disease in Argentina. Epidemiology & Infection, 2019;V.147, e311.